Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug. 7 /EMWNews/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) will host a conference call to discuss second quarter results at 10:00 AM EDT Monday, August 11, 2008. A live Webcast of the conference call can be accessed through the company's website at: http://www.emisphere.com. The live conference call dial-in number is: 1-800-894-5910 (United States and Canada) or 1-785-424-1052 (International). In addition, an archive of the Webcast can be accessed through the same link; an audio replay of the call will be available following the conference call by calling 1-800-283-5758 (United States and Canada) or 1-402-220-0863 (International). ABOUT EMISPHERE TECHNOLOGIES, INC. Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules, pharmaceutical compounds and nutritional supplements using its Eligen(R) Technology. Some of these molecules or compounds can only be given by injection; when combined with our technology convenient oral versions may be safe, effective and provide significant advantages. The benefits of other compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. In those cases, use of Emisphere's technology can improve the therapeutic effectiveness of the compounds. The Eligen(R) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com. Safe Harbor Statement Regarding Forward-looking Statements The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 17, 2008 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed on May 7, 2008.
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89